In chronic lymphocytic leukemia (CLL), AKT inhibitors and mTOR inhibitors (Torin-1) effectively restore CMA activity while removing prooncogenic proteins involved in leukemia initiation and progression [66]. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.